Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.
Related to this article
MT027, an off-the-shelf B7-H3–directed CAR T-cell therapy, earned FDA fast track designation for recurrent glioblastoma.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
2
August Roundup of FDA Approvals in Oncology: Daraxonrasib Highlights 5 Decisions to Know
3
European Commission Approves T-DXd Plus Pertuzumab for First-Line HER2+ Metastatic Breast Cancer
4
Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments
5